IL152726A0 - Adenosine a2a receptor antagonists - Google Patents

Adenosine a2a receptor antagonists

Info

Publication number
IL152726A0
IL152726A0 IL15272601A IL15272601A IL152726A0 IL 152726 A0 IL152726 A0 IL 152726A0 IL 15272601 A IL15272601 A IL 15272601A IL 15272601 A IL15272601 A IL 15272601A IL 152726 A0 IL152726 A0 IL 152726A0
Authority
IL
Israel
Prior art keywords
adenosine
receptor antagonists
antagonists
receptor
Prior art date
Application number
IL15272601A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL152726A0 publication Critical patent/IL152726A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL15272601A 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists IL152726A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20714300P 2000-05-26 2000-05-26
PCT/US2001/016954 WO2001092264A1 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
IL152726A0 true IL152726A0 (en) 2003-06-24

Family

ID=22769372

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15272601A IL152726A0 (en) 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists
IL152726A IL152726A (en) 2000-05-26 2002-11-10 Derivatives of 5-amino- {pyrazolo- [3,4-e] -4,2,1-triazolo [5,1-c] pyrimidine} converted at positions 2 and 7 as adenosine A2A receptor inhibitors
IL220174A IL220174A (en) 2000-05-26 2012-06-04 Acidic Salts of 5-Amino History- {Pyrazolo [3,4- e] –4,2,1- Triazolo [5,1– c] pyrimidine} preserved in positions 2 and 7 and pharmaceutical preparations coating them

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL152726A IL152726A (en) 2000-05-26 2002-11-10 Derivatives of 5-amino- {pyrazolo- [3,4-e] -4,2,1-triazolo [5,1-c] pyrimidine} converted at positions 2 and 7 as adenosine A2A receptor inhibitors
IL220174A IL220174A (en) 2000-05-26 2012-06-04 Acidic Salts of 5-Amino History- {Pyrazolo [3,4- e] –4,2,1- Triazolo [5,1– c] pyrimidine} preserved in positions 2 and 7 and pharmaceutical preparations coating them

Country Status (31)

Country Link
US (4) US6630475B2 (US07981874-20110719-C00313.png)
EP (1) EP1283839B1 (US07981874-20110719-C00313.png)
JP (3) JP4574112B2 (US07981874-20110719-C00313.png)
KR (1) KR100520907B1 (US07981874-20110719-C00313.png)
CN (2) CN1247588C (US07981874-20110719-C00313.png)
AR (1) AR028621A1 (US07981874-20110719-C00313.png)
AT (1) ATE293627T1 (US07981874-20110719-C00313.png)
AU (2) AU2001268089C1 (US07981874-20110719-C00313.png)
BR (1) BRPI0111015B8 (US07981874-20110719-C00313.png)
CA (1) CA2410237C (US07981874-20110719-C00313.png)
CZ (1) CZ303790B6 (US07981874-20110719-C00313.png)
DE (1) DE60110219T2 (US07981874-20110719-C00313.png)
DK (1) DK1283839T3 (US07981874-20110719-C00313.png)
EC (1) ECSP024364A (US07981874-20110719-C00313.png)
ES (1) ES2237576T3 (US07981874-20110719-C00313.png)
HK (1) HK1049007B (US07981874-20110719-C00313.png)
HU (1) HU230420B1 (US07981874-20110719-C00313.png)
IL (3) IL152726A0 (US07981874-20110719-C00313.png)
MX (1) MXPA02011625A (US07981874-20110719-C00313.png)
MY (1) MY132006A (US07981874-20110719-C00313.png)
NO (1) NO325008B1 (US07981874-20110719-C00313.png)
NZ (1) NZ522326A (US07981874-20110719-C00313.png)
PE (1) PE20020062A1 (US07981874-20110719-C00313.png)
PL (1) PL218764B1 (US07981874-20110719-C00313.png)
PT (1) PT1283839E (US07981874-20110719-C00313.png)
RU (1) RU2315053C2 (US07981874-20110719-C00313.png)
SI (1) SI1283839T1 (US07981874-20110719-C00313.png)
SK (1) SK287748B6 (US07981874-20110719-C00313.png)
TW (1) TWI288137B (US07981874-20110719-C00313.png)
WO (1) WO2001092264A1 (US07981874-20110719-C00313.png)
ZA (1) ZA200208898B (US07981874-20110719-C00313.png)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100520907B1 (ko) * 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
US6916811B2 (en) * 2001-11-30 2005-07-12 Schering Corporation Adenosine A2a receptor antagonists
MXPA04005158A (es) 2001-11-30 2004-08-11 Schering Corp Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.
WO2003063876A2 (en) 2002-01-28 2003-08-07 Kyowa Hakko Kogyo Co., Ltd. Methods of treating patients suffering from movement disorders
JP2005527635A (ja) * 2002-05-30 2005-09-15 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド 三環ピラゾロトリアゾロピリミジン環構造を有する薬学的に活性な化合物及び使用方法
US7414058B2 (en) * 2002-12-19 2008-08-19 Schering Corporation Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20070010522A1 (en) 2003-04-09 2007-01-11 Chi Vu Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
TWI375677B (en) * 2003-04-23 2012-11-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
ATE481101T1 (de) * 2003-06-10 2010-10-15 Kyowa Hakko Kirin Co Ltd Verfahren zur behandlung von angstzuständen
EP1636187A1 (en) * 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
EP1678168B1 (en) * 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
MXPA06004722A (es) 2003-10-28 2006-07-05 Schering Corp Procedimiento para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas sustituidas.
WO2005054245A2 (en) * 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
ATE516011T1 (de) * 2003-12-19 2011-07-15 Schering Corp Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten
TW200538118A (en) 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
WO2006132275A1 (ja) * 2005-06-07 2006-12-14 Kyowa Hakko Kogyo Co., Ltd. 運動障害の予防および／または治療剤
US7465740B2 (en) 2005-09-19 2008-12-16 Schering Corporation 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
WO2009110955A2 (en) * 2008-02-29 2009-09-11 Albert Einstein College Of Medicine Of Yeshiva University Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof
WO2009111449A1 (en) 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
CN102014959B (zh) 2008-03-10 2016-01-20 康奈尔大学 血脑屏障通透性的调节
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
EP2322223A4 (en) 2008-07-23 2012-08-22 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST MIGRAINE
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
CA2750265A1 (en) 2009-01-20 2010-07-29 Marc Cantillon Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010103547A2 (en) 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
TW201100427A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted heterocyclic compounds
US8537177B2 (en) * 2009-06-15 2013-09-17 Marvell World Trade Ltd. System and methods for gamut bounded saturation adaptive color enhancement
US8598343B2 (en) 2009-08-07 2013-12-03 Merck Sharp & Dohme Corp. Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
SI2598482T1 (sl) 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba
US9006177B2 (en) * 2010-09-24 2015-04-14 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
WO2012129381A1 (en) * 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2013024474A1 (en) * 2011-08-18 2013-02-21 Mapi Phrarma Ltd. Polymorphs of preladenant
MY187638A (en) 2011-10-20 2021-10-06 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
WO2014071512A1 (en) * 2012-11-06 2014-05-15 Universite Laval Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN107106558A (zh) 2014-11-18 2017-08-29 默沙东公司 具有a2a拮抗剂性质的氨基吡嗪化合物
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
MX2019011743A (es) * 2017-03-30 2020-01-20 Iteos Therapeutics Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres.
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
IL275817B2 (en) * 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, preparations and their medical applications
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
CN108276345A (zh) * 2018-03-22 2018-07-13 重庆奥舍生物化工有限公司 一种药物中间体嘧啶-5-甲醛的制备方法
SG11202009706VA (en) * 2018-04-08 2020-10-29 Beigene Ltd Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
WO2020112700A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210116488A (ko) 2018-12-20 2021-09-27 인사이트 코포레이션 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220235056A1 (en) * 2019-05-03 2022-07-28 Nektar Therapeutics Adenosine 2 receptor antagonists
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
WO2021011670A1 (en) * 2019-07-17 2021-01-21 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists and uses thereof
CN112592346B (zh) 2019-07-30 2022-04-26 厦门宝太生物科技股份有限公司 一种a2a和/或a2b抑制剂中间体的制备方法
CN112592354B (zh) 2019-07-30 2022-05-27 厦门宝太生物科技股份有限公司 一种异噁唑并嘧啶类杂环化合物的制备方法
CN111072675A (zh) * 2019-12-12 2020-04-28 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
JP7431665B2 (ja) 2020-05-20 2024-02-15 Ykk Ap株式会社 接合構造および建具
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU466232A1 (ru) * 1973-05-23 1975-04-05 Киевский Ордена Ленина Государственный Университет Им.Т.Г.Шевченко Споссоб получени конденсированных пиримидо- -триазиниевых соединений с мостиковыми атомами азота
DE3677445D1 (de) 1985-09-30 1991-03-14 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,5-c)-pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
SU1739850A3 (ru) * 1987-08-31 1992-06-07 Такеда Кемикал Индастриз, Лтд (Фирма) Способ получени конденсированных производных пиразоло[3,4- @ ]пиримидина
IT1264901B1 (it) * 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ES2165393T3 (es) 1993-07-27 2002-03-16 Kyowa Hakko Kogyo Kk Remedio contra la enfermedad de parkinson.
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) * 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
KR100520907B1 (ko) * 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
US6916811B2 (en) * 2001-11-30 2005-07-12 Schering Corporation Adenosine A2a receptor antagonists
US7414058B2 (en) * 2002-12-19 2008-08-19 Schering Corporation Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
MXPA06004722A (es) * 2003-10-28 2006-07-05 Schering Corp Procedimiento para preparar 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pirimidinas sustituidas.
WO2005054245A2 (en) * 2003-12-01 2005-06-16 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
TW200538118A (en) * 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
US7465740B2 (en) * 2005-09-19 2008-12-16 Schering Corporation 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
CA2410237A1 (en) 2001-12-06
US20040023997A1 (en) 2004-02-05
US6897216B2 (en) 2005-05-24
AU2001268089C1 (en) 2006-04-13
BR0111015A (pt) 2005-01-11
JP2007145875A (ja) 2007-06-14
AU6808901A (en) 2001-12-11
MY132006A (en) 2007-09-28
CZ303790B6 (cs) 2013-05-09
CN1800186A (zh) 2006-07-12
HK1049007A1 (en) 2003-04-25
HU230420B1 (hu) 2016-05-30
EP1283839A1 (en) 2003-02-19
IL220174A (en) 2015-07-30
DK1283839T3 (da) 2005-07-25
KR20030003746A (ko) 2003-01-10
NZ522326A (en) 2006-03-31
HK1049007B (zh) 2005-09-16
SK16712002A3 (sk) 2003-08-05
CZ20023886A3 (cs) 2003-02-12
DE60110219T2 (de) 2006-03-09
USRE44205E1 (en) 2013-05-07
NO20025651D0 (no) 2002-11-25
PT1283839E (pt) 2005-08-31
JP2003535094A (ja) 2003-11-25
BRPI0111015B1 (pt) 2017-11-07
KR100520907B1 (ko) 2005-10-11
MXPA02011625A (es) 2003-03-27
PL218764B1 (pl) 2015-01-30
JP4574112B2 (ja) 2010-11-04
DE60110219D1 (de) 2005-05-25
CN100384847C (zh) 2008-04-30
US20050026932A1 (en) 2005-02-03
JP2006219497A (ja) 2006-08-24
PE20020062A1 (es) 2002-02-02
IL152726A (en) 2012-07-31
ZA200208898B (en) 2004-03-01
WO2001092264A1 (en) 2001-12-06
CN1247588C (zh) 2006-03-29
BRPI0111015B8 (pt) 2021-05-25
JP4938348B2 (ja) 2012-05-23
HUP0600239A2 (en) 2006-07-28
PL360472A1 (en) 2004-09-06
US7067655B2 (en) 2006-06-27
SI1283839T1 (US07981874-20110719-C00313.png) 2005-08-31
EP1283839B1 (en) 2005-04-20
ATE293627T1 (de) 2005-05-15
SK287748B6 (sk) 2011-08-04
HUP0600239A3 (en) 2008-06-30
CN1451007A (zh) 2003-10-22
NO325008B1 (no) 2008-01-14
RU2315053C2 (ru) 2008-01-20
ECSP024364A (es) 2003-03-31
AR028621A1 (es) 2003-05-14
ES2237576T3 (es) 2005-08-01
US20020099061A1 (en) 2002-07-25
US6630475B2 (en) 2003-10-07
TWI288137B (en) 2007-10-11
IL220174A0 (en) 2012-07-31
NO20025651L (no) 2003-01-23
CA2410237C (en) 2008-01-08
AU2001268089B2 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
AU6808901A (en) Adenosine a2a receptor antagonists
IL161572A0 (en) Adenosine a2a receptor antagonists
HK1063780A1 (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
IL155712A0 (en) Aminothiazoles and their use as adenosine receptor antagonists
IL147198A0 (en) N-pyrazole a2a receptor agonists
IL147195A0 (en) C-pyrazole a2a receptor agonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
IL175759A0 (en) A2b adenosine receptor antagonists
AP2003002807A0 (en) Compounds specific to adenosine a1 a2a and a3 receptor and uses thereof
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
HK1059927A1 (en) Condensed purine derivatives as a1 adenosine receptor antagonists
NO20020979D0 (no) Selektive A2B-adenosin reseptorantagonister
AU3167402A (en) Aminotriazolopyridiine derivatives as adenosine receptor ligands
HK1047750A1 (zh) 趨化因子受體拮抗劑
GB0000474D0 (en) Receptor
AU1252102A (en) Receptor
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
EP1295891A4 (en) nucleoside
GB0010292D0 (en) A adenosine receptor agonists
GB0014761D0 (en) Receptor
GB0031096D0 (en) Receptor
GB0009269D0 (en) Receptor
HUP0203369A3 (en) Polycycloalkylpurines as adenosine receptor antagonists, process for their preparation and their use